Combination therapy for stomach cancer spread to the abdomen
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of treatments for stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink or control the cancer, potentially making surgery possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not had any prior chemotherapy, radiation, or other cancer treatment.
- You are between 18 and 75 years old.
- You have a type of stomach cancer called adenocarcinoma that is HER2-negative and has a PD-L1 CPS score of 1 or higher.
- Surgery or a scope exam shows cancer cells in the abdomen or limited spread with a PCI score of 10 or less.
- You are otherwise healthy enough for treatment, with normal blood counts and organ function.
- You are not pregnant or breastfeeding, and you are willing to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a specialized chemotherapy delivery method called PIPAC—where chemotherapy is sprayed directly into the abdomen under pressure—for patients with gastric cancer that has spread to the abdominal lining. The goal is to deliver stronger doses of chemotherapy directly to where the cancer is, potentially helping patients who aren't candidates for major surgery.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial studies a combination treatment for stomach cancer that has spread to the lining of the abdomen. It uses a special way to deliver heated chemotherapy directly into the abdomen, along with an immunotherapy drug that helps your immune system attack the cancer.
This trial tests a treatment called HIPEC (heated chemotherapy given directly into the abdomen during surgery) for stomach cancer that has spread to the lining of the belly. The goal is to see if this approach can help remove or shrink the cancer and improve outcomes.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
Hear when a new Gastric Cancer Peritoneal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.